Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
120.13B
Market cap120.13B
Price-Earnings ratio
13.47
Price-Earnings ratio13.47
Dividend yield
4.10%
Dividend yield4.10%
Average volume
14.23M
Average volume14.23M
High today
$61.00
High today$61.00
Low today
$58.33
Low today$58.33
Open price
$59.81
Open price$59.81
Volume
19.24M
Volume19.24M
52 Week high
$68.64
52 Week high$68.64
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 120.13B, Bristol-Myers Squibb(BMY) trades at $58.80. The stock has a price-to-earnings ratio of 13.47 and currently yields dividends of 4.10%.

On 2026-10-05, Bristol-Myers Squibb(BMY) stock traded between a low of $58.33 and a high of $61.00. Shares are currently priced at $58.80, which is +0.8% above the low and -3.6% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 19.24M, against a daily average of 14.23M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

BMY News

MarketWatch 6h
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch

...

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
TipRanks 14h
Immunome Restructures BMS Deal, Gains Key Patent Rights

An announcement from Immunome ( (IMNM) ) is now available. On October 2, 2026, Immunome, Inc. amended its long-standing license agreement with Bristol-Myers Sq...

Zacks 14h
Are Investors Undervaluing Bristol Myers Squibb Right Now?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop t...

Are Investors Undervaluing Bristol Myers Squibb Right Now?

Analyst ratings

61%

of 31 ratings
Buy
32.3%
Hold
61.3%
Sell
6.5%

More BMY News

The Motley Fool 4d
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Bristol Myers Squibb: Slow and Steady Revenue Growth Bristol Myers Squibb (BMY -1.23%) operates as a global biopharmaceutical entity that researches, develops,...

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
TipRanks 5d
Bristol-Myers Squibb: Pipeline Risks Balance Core Strengths, Justifying Hold Rating and Unchanged $60 Price Target

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $60.00. Evan Seigerman has given his Hol...

TipRanks 5d
Bristol Myers expands Champions in Care program with $1M in grant awards

Bristol Myers (BMY) announced the expansion of Champions in Care, the company’s initiative honoring healthcare professionals, or HCPs, first launched in 2025. A...

TipRanks 5d
Bristol-Myers Squibb’s Real‑World Luspatercept Study Wraps Up, Setting the Stage for Next Growth Moves

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has completed a real‑world study titled “Tre...

24/7 Wall St. 5d
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric

Investing Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric Bristol Myers Squibb has raised its dividend for 17 straight ye...

Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric
Simply Wall St 7d
Why Is Bristol-Myers Squibb In Focus After New Phase 3 Myeloma Data?

Bristol-Myers Squibb (NYSE:BMY) reported the first Phase 3 EXCALIBER-RRMM results for ZENBEXUS in relapsed or refractory multiple myeloma. The pivotal trial sh...

Why Is Bristol-Myers Squibb In Focus After New Phase 3 Myeloma Data?

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.